Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 3, 2006, Pages 539-541

  Hepstinstall, S ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY STENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; MAINTENANCE DRUG DOSE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREMEDICATION; RECURRENCE; STENTS; SYNDROME; TICLOPIDINE;

EID: 33645967456     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01777.x     Document Type: Note

References (36)

1. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005; 294: 1224-32.
2. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet J-L, Alessi M-C. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; DOI: 10.1111/j.1538-7836.2005.01751.x
3. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
4. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
5. Müller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
6. von Beckerath N, Taubert D, Pogatsa-Murray G, Wieczorek A, Schomig E, Schomig A, Kastrati A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 2005; 93: 789-91.
7. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-32.
8. Hochholzer W, Trenk D, Fischer B, Andris K, Bestehorn H-P, Buettner HJ, Neumann F-J. Impact of peri-interventional platelet inhibition after loading with clopidogrel on 30-days clinical outcome of elective coronary stent placement: The Excelsior Study. Eur Soc Cardiol Congr 2005; Abstract P2230.
9. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: Implications for thrombotic events and restenosis. Platelets 2004; 15: 95-9.
10. Heptinstall S, Glenn JR, May JA, Storey RF, Wilcox RG. Clopidogrel resistance. Catheter Cardiovasc Interv 2004; 63: 397-8.
11. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
12. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
13. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Pre-existent variability in platelet response to ADP accounts for "Clopidogrel Resistance" J Thromb Haemost 2005; 3 (Suppl. 1): Abstract P0955.
14. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
15. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311 -6.
16. Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Ernest CS, Jansen M, Jakubowski JA, Naganuma H, Wiviott SD, Winters KJ. Superior inhibition of platelet aggregation following a loading dose of CS-747 (prasugrel, LY640315) versus clopidogrel: Correlation with the pharmacokinetics of active metabolite generation. J Thromb Haemost 2005; 3 (Suppl. 1): Abstract P0952.
17. Angiolillo DJ, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Pignatti PF, Fernandez-Ortiz A, Macaya C. Pharmacogenetic modulation of clopidogrel antiplatelet effects: Role of gene sequence variations of the CYP3A4 enzyme. ESC Congr 2005; Abstract P3510.
18. 12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets (in press).
19. Ford I, Williams D. Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel? Platelets 2004; 15: 201-5.
20. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005; 45: 1157-64.
21. 12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Coagul Fibrinolysis 2005; 16: 199-204.
22. 12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491-7.
23. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, Himbert D, Baruch D, Guillin MC, Steg PG. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: A case-control study. J Am Coll Cardiol 2005; 45: 1753-6.
24. 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-34.
25. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-10.
27. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-9.
28. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-6.
29. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-4.
30. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600- and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-50.
31. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005; 111: 1153-9.
32. Brandt JT, Payne CD, Weerakkody G, Behounek BD, Naganuma H, Jakubowski JA, Wiviott SD, Winters KJ. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J Am Coll Cardiol 2005; 45 (Suppl. 1): 87A.
33. Asai F, Jakubowski JA, Winters KJ, Hirota T, Matsushima N, Naganuma H, Freestone S. A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. J Am Coll Cardiol 2005; 45 (Suppl. 1): 87A.
34. 12 receptor antagonist, compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease. J Am Coll Cardiol 2005; 45 (Suppl. 1): 416A.
35. Husted S, Emanuelsson H, Heptinstall S, Clark S, Peters G. Greater and less variable inhibition of platelet aggregation (IPA) with AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with atherosclerosis. ESC Congr 2005; Abstract 3764.
36. 12 antagonists. Semin Thromb Hemost 2005; 31: 195-204.